サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363084

大腸がん治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、地域別、セグメント別予測、2023年～2030年

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
大腸がん治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月20日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

大腸がん治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の大腸がん治療薬市場規模は2030年までに167億米ドルに達すると予測され、2023年から2030年までのCAGRは4.7%です。

対象人口の増加や標的療法の採用増加など、いくつかの要因が市場成長を促進すると予測されています。

パイプラインにある製品は、大腸がん（CRC）市場のアンメットニーズの一部を満たそうとしています。もし承認されれば、Array Biopharma社のセツキシマブとエンコラフェニブの併用療法は、BRAF変異型mCRC治療に適応を持つ最初の治療薬となります。住友大日本製薬のナパブカシンは、STAT-3を標的とするがん幹細胞阻害剤です。

切除可能な高リスク大腸がんに対するアジュバント/ネオアジュバント治療薬はほとんどないです。このような状況におけるパイプライン薬剤の欠如は、切除された患者の治癒率を改善できる効果的な治療法を開発する絶好の機会です。現在、切除可能なCRCに対する利用可能な治療法のほとんどは、安価な化学療法レジメンとジェネリック医薬品です。

ロシュのアバスチン、アムジェンのベクティビックス、サノフィのザルトラップといった主要製品の特許切れが間近に迫っており、バイオシミラーの浸透が予想されます。アムジェン/アラガンのMvasiは、2017年に米国で、2018年に欧州でそれぞれアバスチンのバイオシミラーとして初の承認を取得しました。シズマブとクラベバは、インドで発売されたアバスチンのバイオシミラーの一部です。その他、アバスチンとアービタックスのバイオシミラーがいくつか開発中です。

大腸がん治療薬市場レポート・ハイライト

  • アバスチンやアービタックスのような標的治療薬の採用増加により、2022年の薬剤クラス別では免疫療法が市場を独占。
  • 化学療法は、非特異性、副作用、薬剤耐性の市場開拓により市場シェアを失う可能性が高いです。しかし、オプジーボやキイトルーダなどの抗PD1薬が最近発売され、その標的指向の作用機序により、現在の状況は一変しそうです。
  • 国別では米国が最大のシェアを占め、疾病負担の増大、治療率の上昇、薬剤費の高騰により、2022年までその優位性を維持すると予測されます。
  • ロシュは、アバスチンの使用量増加により、2022年の大腸がん産業界をリードしました。アバスチンは2022年に最も高い収益を上げるCRC治療薬でした。しかし、ロシュはアバスチンの特許切れとバイオシミラーの浸透を理由に市場シェアを失うと予測されています。
  • ブリストル・マイヤースクイブとメルクは、オプジーボやキイトルーダなどの標的治療薬の採用増加により、2022年までに大腸がん治療薬市場のマーケットリーダーになると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 大腸がん治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 大腸がん治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 大腸がん治療薬市場：薬剤クラス別推定・動向分析

  • 大腸がん治療薬市場：重要なポイント
  • 大腸がん治療薬市場：動向と市場シェア分析、2022年および2030年
  • 化学療法
  • 免疫療法
  • その他

第5章 大腸がん治療薬市場：地域別推定・動向分析

  • 地域別の見通し
  • 地域別の大腸がん治療薬市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Amgen, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Lilly
    • Merck & co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Sanofi
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Canada colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Europe colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Europe colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 UK colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 France colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Italy colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Spain colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Sweden colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Norway colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Denmark colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 China colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 India colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Australia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Thailand colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 South Korea colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Latin America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Latin America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Mexico colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Argentina colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 UAE colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Kuwait colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Colorectal cancer therapeutics: Market outlook
  • Fig. 9 Colorectal cancer therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Colorectal cancer therapeutics market driver impact
  • Fig. 15 Colorectal cancer therapeutics market restraint impact
  • Fig. 16 Colorectal cancer Therapeutics market strategic Initiatives analysis
  • Fig. 17 Colorectal cancer therapeutics market: Drug class movement analysis
  • Fig. 18 Colorectal cancer therapeutics market: Drug class outlook and key takeaways
  • Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global Colorectal Cancer Therapeutics market: Regional Movement Analysis
  • Fig. 23 Global Colorectal cancer therapeutics market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-512-0

Colorectal Cancer Therapeutics Market Growth & Trends:

The global colorectal cancer therapeutics market size is expected to reach USD 16.7 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.7% from 2023 to 2030. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Colorectal Cancer Therapeutics Market Report Highlights:

  • Immunotherapy dominated the market based on drug class in 2022, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
  • Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
  • U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
  • Roche led the colorectal cancer industrial setting in 2022 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2022. However, Roche is projected to lose market share on grounds of Avastin's patent expiry and biosimilar penetration
  • Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug class
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Colorectal Cancer Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Colorectal Cancer Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Colorectal Cancer Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Colorectal Cancer Therapeutics Market: Key Takeaways
  • 4.2. Colorectal Cancer Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Colorectal Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Colorectal Cancer Therapeutics Market by Region: Key Takeaway
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Amgen, Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bayer AG
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Bristol-Myers Squibb Company
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Lilly
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Merck & co., Inc.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Sanofi
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives